Simplify Logo

Full-Time

Associate Director – Sr. Medical Science Liaison

Central

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$200k - $235kAnnually

+ Performance Bonus + Equity + Health Benefits

Mid, Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Candidates with a PharmD, Ph.D., MD, Genetic Counseling, as well as other advanced healthcare degrees or relevant experience, will be considered
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance
  • Excellent interpersonal communication and presentation skills (including networking)
  • Able to participate in a scientific dialogue with KOL’s and researchers
  • Excellent teaching skills and ability to present and discuss scientific material clearly and concisely
  • Proven ability to create and sustain relationships with industry leaders
  • Skilled in clinical research and an understanding of the process of pharmaceutical product development and approval
  • Demonstrated ability to organize, prioritize, and work effectively with minimal supervision in a constantly changing environment
  • Travel 50-60% of the time depending on territory size; evening and weekend work will be involved with some variation based upon the demands of the business imperatives
Responsibilities
  • Developing relationships with various healthcare professionals and providing them with credible, fair, balanced, scientific information
  • Be a major source of balanced medical information for HCPs and will be skilled in issues management and addressing unsolicited questions about safety and off-label use of products based on available scientific data
  • Territory planning, identifying new external stakeholders, and understanding therapeutic area educational and data gaps in the community will be key activities. This plan may be dynamic with respect to the molecule, molecule life-cycle, therapeutic area, and territory. The Senior MSL will liaise with key internal stakeholders to build a comprehensive action-oriented plan
  • Expected to become a therapeutic area and product expert. This will be evidenced by regular review of relevant literature and participation in scientific congresses and conferences, including training sessions, to establish and maintain an up-to-date knowledge base
  • Be instrumental in internal training and communication. Knowledge sharing, including KOL and site profiling, and education both internally and externally will be a key area of responsibility
  • Assist in the identification of potential investigators and research projects. This may include assistance with investigator-sponsored trial process, sponsored study site identification, recruitment strategies, and collaboration with clinical operations

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

7%

1 year growth

46%

2 year growth

58%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.